tradingkey.logo

Pluri Inc

PLUR
查看詳細走勢圖
3.460USD
+0.010+0.29%
收盤 12/19, 16:00美東報價延遲15分鐘
28.24M總市值
虧損本益比TTM

Pluri Inc

3.460
+0.010+0.29%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.29%

5天

+12.34%

1月

-11.28%

6月

-12.66%

今年開始到現在

-19.06%

1年

-28.22%

查看詳細走勢圖

TradingKey Pluri Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Pluri Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名169/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價12.00。中期看,股價處於下降通道。近一個月,市場表現較差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Pluri Inc評分

相關信息

行業排名
169 / 404
全市場排名
300 / 4582
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 1 分析師
買入
評級
12.000
目標均價
+283.39%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Pluri Inc亮點

亮點風險
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
業績高增長
公司營業收入穩步增長,連續3年增長365.51%
業績增長期
公司處於發展階段,最新年度總收入1.34M美元
估值合理
公司最新PE估值-1.08,處於3年歷史合理位
機構加倉
最新機構持股1.60M股,環比增加1.49%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉33.92K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.76

Pluri Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Pluri Inc簡介

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
公司代碼PLUR
公司Pluri Inc
CEOYanay (Yaky)
網址https://pluri-biotech.com/

常見問題

Pluri Inc(PLUR)的當前股價是多少?

Pluri Inc(PLUR)的當前股價是 3.460。

Pluri Inc 的股票代碼是什麼?

Pluri Inc的股票代碼是PLUR。

Pluri Inc股票的52週最高點是多少?

Pluri Inc股票的52週最高點是7.130。

Pluri Inc股票的52週最低點是多少?

Pluri Inc股票的52週最低點是2.820。

Pluri Inc的市值是多少?

Pluri Inc的市值是28.24M。

Pluri Inc的淨利潤是多少?

Pluri Inc的淨利潤為-22.58M。

現在Pluri Inc(PLUR)的股票是買入、持有還是賣出?

根據分析師評級,Pluri Inc(PLUR)的總體評級為買入,目標價格為12.000。

Pluri Inc(PLUR)股票的每股收益(EPS TTM)是多少

Pluri Inc(PLUR)股票的每股收益(EPS TTM)是-3.137。
KeyAI